title: Serum ficolin-2 in hospitalised patients with community-acquired pneumonia.
abstract: Mannose binding lectin (MBL) and ficolins contribute to host defence through activation of the lectin pathway of complement. In this study, serum levels of ficolin-2 and MBL were determined in 276 patients with community-acquired pneumonia (CAP). MBL deficiency and ficolin-2 insufficiency were defined using previously validated cut-offs. No differences were observed in MBL or ficolin-2 between patients and controls. MBL-deficient patients (<500 ng/ml) were not at higher risk of 30-day mortality odds ratio (OR) 0.97 (0.38-2.48,p=0.9) or a composite outcome of mortality, mechanical ventilation, vasopressor support (MV/VS) or complications OR 0.89 (0.44-1.77, p=0.9). Although no significant relationship between ficolin-2 insufficiency and outcome was observed, very low ficolin-2 levels (<1,200 ng/ml) were associated with an OR 1.23 (0.15-10.1), p=0.6 for 30-day mortality, 3.05 (0.61-15.2, p=0.2) for MV/VS and OR 2.05 (0.52-8.1, p=0.2) for the composite outcome. Low serum levels of MBL and ficolin-2 are not associated with CAP susceptibility. The high frequency of ficolin-2 insufficiency in patients with severe CAP would justify a larger investigation of ficolin-2 as a modifier of CAP severity.
authors.affiliation: Tayside Respiratory Research Group, University of Dundee, Dundee, UK, jchalmers@dundee.ac.uk.
authors.forename: James D
authors.initials: JD
authors.lastname: Chalmers
authors.forename: Gilly B
authors.initials: GB
authors.lastname: Fleming
authors.forename: Julia
authors.initials: J
authors.lastname: Rutherford
authors.forename: Misao
authors.initials: M
authors.lastname: Matsushita
authors.forename: David C
authors.initials: DC
authors.lastname: Kilpatrick
authors.forename: Adam T
authors.initials: AT
authors.lastname: Hill
mesh_terms: D000328:Adult; D000368:Aged; D015415:Biomarkers / Q000097:blood; D015331:Cohort Studies; D017714:Community-Acquired Infections / Q000097:blood / Q000175:diagnosis; D005260:Female; D006760:Hospitalization / Q000639:trends; D006801:Humans; D037102:Lectins / Q000097:blood*; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D011014:Pneumonia / Q000097:blood* / Q000175:diagnosis*; D000097604:Ficolins
chemical_list: D015415:Biomarkers; D037102:Lectins; D000097604:Ficolins
references.citation: J Immunol. 2008 Mar 15;180(6):4124-32
references.pmid: 18322223
references.citation: Lancet. 2002 May 4;359(9317):1569-73
references.pmid: 12047967
references.citation: Eur Respir J. 2012 Jan;39(1):187-96
references.pmid: 21737556
references.citation: Nature. 1997 Apr 3;386(6624):506-10
references.pmid: 9087411
references.citation: J Innate Immun. 2010;2(2):114-22
references.pmid: 20375630
references.citation: Crit Care Med. 2011 Jun;39(6):1388-93
references.pmid: 21317643
references.citation: QJM. 2009 Jun;102(6):379-88
references.pmid: 19299247
references.citation: Clin Respir J. 2009 Jan;3(1):29-33
references.pmid: 20298369
references.citation: Proc Natl Acad Sci U S A. 2002 Dec 24;99(26):16969-74
references.pmid: 12477926
references.citation: J Biomed Biotechnol. 2012;2012:138797
references.pmid: 22500076
references.citation: Hum Mol Genet. 2005 Jun 15;14(12):1651-8
references.pmid: 15879437
references.citation: Mol Immunol. 2007 May;44(12):3267-70
references.pmid: 17382393
references.citation: J Allergy Clin Immunol. 2008 Aug;122(2):368-74, 374.e1-2
references.pmid: 18582923
references.citation: J Infect Dis. 2004 Mar 1;189(5):785-96
references.pmid: 14976594
references.citation: N Engl J Med. 1997 Jan 23;336(4):243-50
references.pmid: 8995086
references.citation: Infect Immun. 1996 Nov;64(11):4850-3
references.pmid: 8890251
references.citation: Eur Respir J. 2011 Apr;37(4):858-64
references.pmid: 20729221
references.citation: Thorax. 2010 Oct;65(10):878-83
references.pmid: 20729231
references.citation: Lancet Respir Med. 2013 May;1(3):224-32
references.pmid: 24429128
references.citation: Emerg Infect Dis. 2008 May;14(5):727-33
references.pmid: 18439353
references.citation: N Engl J Med. 2009 Jun 18;360(25):2637-44
references.pmid: 19535802
references.citation: Am J Respir Crit Care Med. 2003 Aug 15;168(4):476-80
references.pmid: 12746253
references.citation: Scand J Immunol. 2007 Apr;65(4):383-92
references.pmid: 17386030
references.citation: J Biol Chem. 1996 Feb 2;271(5):2448-54
references.pmid: 8576206
references.citation: Clin Infect Dis. 2008 Aug 15;47(4):510-6
references.pmid: 18611155
references.citation: Clin Infect Dis. 2010 Sep 15;51(6):692-9
references.pmid: 20715907
references.citation: J Infect Dis. 2002 May 15;185(10):1517-20
references.pmid: 11992290
references.citation: PLoS Pathog. 2009 Jan;5(1):e1000282
references.pmid: 19180241
references.citation: JAMA. 1999 Jan 6;281(1):61-6
references.pmid: 9892452
references.citation: Infect Immun. 2005 Feb;73(2):1052-60
references.pmid: 15664949
references.citation: Proc Natl Acad Sci U S A. 2011 May 3;108(18):7523-8
references.pmid: 21502512
references.citation: PLoS Pathog. 2012;8(7):e1002793
references.pmid: 22792067
references.citation: J Immunol. 2012 Dec 15;189(12):5860-6
references.pmid: 23150716